The Means to Monitor Chemical Migration - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Means to Monitor Chemical Migration
Industry associations will soon provide new recommendations about extractables and leachables.

Pharmaceutical Technology
Volume 35, Issue 6, pp. 40-42

The PDA technical report

PDA recently formed a task force to write a technical report about single-use equipment, and part of the document will help the reader address extractables and leachables. The task force includes more than 20 people from biopharmaceutical companies, suppliers, consulting–engineering firms, and regulatory authorities, says Paul Priebe, director of fluid-management technologies at Sartorius Stedim Biotech North America and member of the PDA Single-Use Task Force. PDA plans to publish the report before the end of 2011.

The technical report is intended to be a comprehensive document to guide users in evaluating, qualifying, and implementing single-use systems. The report's main thrust will be the application of risk analysis as the basis for all activities involved in implementing disposable components, including assessing extractables and leachables. "The risk-based approach is not a novel concept, but the formal promotion of this approach in a consensus document should give end users the confidence to use it to implement single-use technologies in their own processes," according to Priebe.

"The goal is to offer a flexible approach to developing a well-designed strategy, so end users can customize their strategy based on their needs and capabilities, thereby developing a robust process that includes process and logistic controls supporting the desired states of patient safety and product availability," says Priebe. For a low-risk application, an end user could develop a strategy based on supplier documentation, but a high-risk application could require validation using process-specific parameters.

Because the document will promote a risk-based approach to qualification and implementation, the task force decided that proposing specific limits or analytical methods would be inappropriate. Instead, the report will refer readers to other documents for guidance, such as the Bio-Process Systems Alliance's guide to extractables and leachables, which readers could use to define their analytical strategy.

One part of controlling extractables and leachables is the careful qualification of equipment suppliers. The technical report will describe how end users can qualify suppliers of single-use systems and what responsibilities the end user should expect the supplier to fulfill. "One key approach championed in the document is developing a partnership with suppliers so that science- and risk-based discussions and decisions can be made effectively during supplier audits and evaluations of single-use system supply chains," says Priebe.

To ensure that it addresses PDA members' concerns about extractables, leachables, and single-use equipment, the task force is developing a tool for the PDA website that will help start a dialog. PDA members also will be able to raise these subjects with the task force during PDA's workshop on single-use systems in Bethesda, Maryland, on Jun. 22–23, 2011.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here